Heart Failure and Cardiomyopathies

The Heart Failure (HF) and Cardiomyopathies Learning Pathway will showcase the latest advances transforming the field of HF, from optimizing guideline-directed medical therapies to breakthrough developments in heart transplantation. Experts will deliver practical, evidence-based strategies for managing complex conditions, including cardiac amyloidosis and hypertrophic cardiomyopathy.

Learn how to navigate the rapidly evolving landscape of cardiomyopathy treatment with an expert-led overview of recent advances in both pharmacologic and non-pharmacologic management strategies (Session 209). Explore the latest diagnostic approaches and targeted treatments for transthyretin (ATTR) cardiac amyloidosis, a condition of growing clinical significance, as experts address key controversies and knowledge gaps (Session 359).

In addition, join a dynamic fireside chat exploring how digital innovation is changing HF care through wearable biosensors, remote monitoring, and predictive AI (Session 335).

Sessions You Don't Want to Miss:

• Equity Isn't Just a Buzz Word: Strategies to Improve Access to HF Therapies For ALL Patients Featuring the Kanu and Docey Chatterjee Keynote presented by Larry A. Allen, MD, FACC (Session 325)
• The Great GDMT Debates: A HF Family Feud (Session 426)
• Pregnancy With a Failing Heart: The Intersection of Cardio-Obstetrics and HF (Session 241)
• Let's Be Real: Initiation and Optimization of Heart Failure Core Medications in Ambulatory and Inpatient Care (Session 217)